Document ID: chunk:federal_register_of_legislation:F2022C00577:front:0:p7
Version: federal_register_of_legislation:F2022C00577
Segment Type: other
Provision Reference: 
Character Range: 17272–20335

(61)      having active epilepsy before the clinical worsening of hypogonadism;
            Note: active epilepsy is defined in the Schedule 1 - Dictionary.
(62)      taking a drug from the Specified List 1 of drugs before the clinical worsening of hypogonadism;
            Note: Specified List 1 of drugs is defined in the Schedule 1 - Dictionary.
(63)      taking an immune checkpoint inhibitor within the 1 year before the clinical worsening of hypogonadism;
            Note: immune checkpoint inhibitor is defined in the Schedule 1 - Dictionary.
(64)      taking a drug from the Specified List 2 of drugs, which cannot be ceased or substituted, at the time of the clinical worsening of hypogonadism;
            Note: Specified List 2 of drugs is defined in the Schedule 1 - Dictionary.
(65)      taking a drug which cannot be ceased or substituted and which is associated in the individual with the clinical worsening of hypogonadism during drug therapy and either:
(a)          the improvement of hypogonadism within 2 months of discontinuing or tapering drug therapy; or
(b)           the clinical worsening of hypogonadism on rechallenge with the same drug; and
where taking the drug continued for at least the 30 days before the clinical worsening of hypogonadism;
(66)      inhaling fumes from a metal from the specified list of metals or a compound containing a metal from the specified list of metals:
(a)          for a cumulative period of at least 2,000 hours before the clinical worsening of hypogonadism; and
(b)          if that exposure has ceased before the clinical worsening of hypogonadism, then that worsening occurred within 2 years of cessation;
            Note: fumes and specified list of metals are defined in the Schedule 1 - Dictionary.
(67)      inhaling, ingesting or having cutaneous contact with a chemical agent from the specified list of chemical agents:
(a)          for a cumulative period of at least 2,000 hours before the clinical worsening of hypogonadism; and
(b)          if that exposure has ceased before the clinical worsening of hypogonadism, then that worsening occurred within 2 years of cessation;
            Note: specified list of chemical agents is defined in the Schedule 1 - Dictionary.
(68)      for females only, inhaling, ingesting or having cutaneous contact with a chemical agent contaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD):
(a)          for a cumulative period of at least 1,000 hours, within a consecutive period of 10 years before the clinical worsening of hypogonadism; and
(b)          if that exposure has ceased before the clinical worsening of hypogonadism, then that worsening occurred within 25 years of cessation;
            Note: inhaling, ingesting or having cutaneous contact with a chemical agent contaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) is defined in the Schedule 1 - Dictionary.
(69)      for females only, having smoked tobacco products:
(a)          in an amount of at least 5 pack-years before the clinical worsening of hypogonadism; and